my fault though, I was such in a rush that I forgot to show two links with two sets of disclosures and Peregrine Pharmaceuticals is indeed missing on the 2014 one... not the 2012 which you did notice already.
Disclosures: Bruce A. Chabner: Sanofi, Allergan, Epizyme, PharmaMar, GlaxoSmithKline, Peregrine, Pharmacyclics (C/A); Eli Lilly (H); Gilead, Merck, Epizyme, Curis, Onyx, Bristol-Myers Squibb, Amgen, Celgene, Exelixis, Rigel (OI).
Recently, the new president of the MD Anderson Cancer Center, Ronald A. DePinho, announced his own “moon shot” to eradicate and cure eight human tumors, including lung, breast, colon, prostate, melanoma, and ovarian cancer [1]. He is marshaling the forces of his cancer center to eliminate these diseases. The effort is labeled a moon shot after the U.S. expedition to the moon, as launched by President Kennedy in 1961. In this case, the feat will harness the tools of modern molecular biology and genetics to find new targets, personalize therapy, and achieve its goal.
Now BioBS2012, now since I have my head on straight and have both to compare with... you may find why I find it interesting and will have to get back to my round of gold to think about it. Even more interesting, we have the very same organization/website = The Oncologist !! so they should have on record that Peregrine disclosure or Bruce Chabner failed to include Peregrine Pharmaceuticals in the 2014 article ?? and why ??
all in a Peregrine day we find so many puzzling pieces...and there must be a reason (also why he leaves out Bristol Myers Squibb : )